KCG Holdings Inc. increased its stake in shares of Antares Pharma, Inc. (NASDAQ:ATRS) by 48.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 66,717 shares of the specialty pharmaceutical company’s stock after buying an additional 21,881 shares during the period. KCG Holdings Inc.’s holdings in Antares Pharma were worth $189,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. boosted its position in Antares Pharma by 80.8% in the first quarter. Thompson Davis & CO. Inc. now owns 68,386 shares of the specialty pharmaceutical company’s stock valued at $194,000 after buying an additional 30,560 shares in the last quarter. M&T Bank Corp bought a new position in Antares Pharma during the first quarter valued at $227,000. Citadel Advisors LLC boosted its position in Antares Pharma by 350.5% in the first quarter. Citadel Advisors LLC now owns 83,882 shares of the specialty pharmaceutical company’s stock valued at $238,000 after buying an additional 65,262 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Antares Pharma by 20.1% in the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after buying an additional 28,029 shares in the last quarter. Finally, Segantii Capital Management Ltd boosted its position in Antares Pharma by 552.4% in the first quarter. Segantii Capital Management Ltd now owns 189,200 shares of the specialty pharmaceutical company’s stock valued at $537,000 after buying an additional 160,200 shares in the last quarter. 32.07% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Antares Pharma, Inc. (ATRS) traded up 2.30% on Friday, hitting $3.12. 869,310 shares of the stock traded hands. Antares Pharma, Inc. has a 52 week low of $1.01 and a 52 week high of $3.37. The stock’s market cap is $486.49 million. The stock has a 50 day moving average price of $3.12 and a 200-day moving average price of $2.73.
Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.01. The firm had revenue of $12.01 million for the quarter, compared to analysts’ expectations of $12.10 million. Antares Pharma had a negative net margin of 41.26% and a negative return on equity of 45.05%. On average, equities research analysts forecast that Antares Pharma, Inc. will post ($0.13) EPS for the current year.
Several research firms have weighed in on ATRS. Vetr raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price target on the stock in a report on Monday, July 24th. Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Wednesday, July 26th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Antares Pharma in a report on Friday, June 23rd. Chardan Capital assumed coverage on shares of Antares Pharma in a report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target on the stock. Finally, Raymond James Financial, Inc. assumed coverage on shares of Antares Pharma in a report on Thursday, April 20th. They set a “strong-buy” rating and a $4.30 target price on the stock. One analyst has rated the stock with a hold rating, three have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $3.83.
In other Antares Pharma news, insider Fred M. Powell purchased 130,000 shares of the stock in a transaction dated Friday, June 9th. The shares were bought at an average price of $2.79 per share, with a total value of $362,700.00. Following the completion of the transaction, the insider now directly owns 331,434 shares in the company, valued at approximately $924,700.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 11.60% of the company’s stock.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
